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Abstract: Diabetes is a leading cause of renal disease. Glomerular mesangial expansion and 
fibrosis are hallmarks of diabetic nephropathy and this is thought to be promoted by infiltration 
of circulating macrophages. Monocyte chemoattractant protein-1 (MCP-1) has been shown to 
attract macrophages in kidney diseases. Glomerular mesangial expansion and fibrosis are 
hallmarks of diabetic nephropathy and this is thought to be promoted by infiltration of circulating 
macrophages. P2X7 receptors (P2X7R) are highly expressed on macrophages and are essential 
components of pro-inflammatory signaling in multiple tissues. Here we show that in diabetic 
patients, renal P2X7R expression is associated with severe mesangial expansion, impaired 
glomerular filtration (40ml/min/1.73 sq. m.), and increased interstitial fibrosis. P2X7R 
activation enhanced the release of MCP-1 in human mesangial cells cultured under high glucose 
conditions. In mice, P2X7R-deficiency prevented glomerular macrophage attraction and collagen 
IV deposition; however, the more severe interstitial inflammation and fibrosis often seen in 
human diabetic kidney diseases was not modelled. Finally, we demonstrate that a P2X7R 
inhibitor (AZ11657312) can reduce renal macrophage accrual following the establishment of 
hyperglycemia in a model of diabetic nephropathy. Collectively these data suggest that P2X7R 
activation may contribute to the high prevalence of kidney disease found in diabetics.  
 















 Renal P2X7 receptor (P2X7R) expression is associated with chronic kidney disease and 
fibrosis in human diabetes 
 Human mesangial P2X7R activates to regulate monocyte chemoattractant release under 
high glucose conditions 
 Genetic loss of murine P2rx7 gene is associated with reduced renal macrophage accrual 
and glomerular fibrosis 
 Chronic inhibition of P2X7R limits renal macrophage accumulation in a model of 
diabetic nephropathy 
 
Research in Context 
The global prevalence of diabetes has doubled in recent decades and is the most common cause 
of kidney failure. Unfortunately, there are few therapeutic options to halt or limit kidney disease 
progression. P2X7R has emerged as a potential target in multiple kidney disease models. We 
have investigated P2X7R expression in diabetic human renal biopsy samples, high-glucose 
treated cells and P2X7R-deficient mice. Our collective findings indicate that kidney P2X7R 
expression causes macrophage accrual and fibrosis in diabetic kidneys. As proof of concept, we 
demonstrate that pharmaceutical inhibition of P2X7R, in a rodent model, prevents the seemingly 














Diabetic kidney disease is becoming a global epidemic (Gross et al., 2005) and is expected to 
increase in prevalence as the diabetic population grows (Shaw et al., 2010). Diabetic 
nephropathy is a unique predictor of mortality in both insulin -dependent and -independent 
diabetes (Afkarian et al., 2013; Groop et al., 2009). Antihypertensive, antiproteinuric and blood-
glucose lowering therapies are the mainstays of treatment. However, despite aggressive blood 
pressure management (Gross et al., 2005; Parving et al., 1983) and hyperglycemic control (The 
Diabetes Control and Complications Trial Research Group, 1993), most diabetic patients 
progress to chronic kidney disease (CKD) and eventually end-stage renal failure.  
 
Diabetic nephropathy is driven by mobilization of major inflammatory cascades (Wada and 
Makino, 2013) that result in glomerular extracellular matrix (ECM) deposition, basement 
membrane thickening, mesangial sclerosis, proteinuria and interstitial fibrosis (Mason and 
Wahab, 2003; Tervaert et al., 2010). Pro-inflammatory signaling may begin in the glomerular 
mesangium (Gómez-Guerrero et al., 2005; Savill et al., 1992). Exposure to a high glucose milieu 
can enhance mesangial secretion of the monocyte chemoattractant protein-1 (MCP-1) resulting 
in macrophage accumulation and glomerulonephritis (Ihm et al., 1998; Wada et al., 2000), 
leading ultimately to fibrosis (Zeisberg and Neilson, 2010). In diabetic patients, the ratio of 
MCP-1 to creatinine is a predictor of reduced glomerular filtration rate (GFR) renal impairment 
(Tam et al., 2009).  
 
Multiple adenosine-5’-triphosphate (ATP)-activated (P2X) receptors and G-protein coupled 
purinergic (P2Y) receptors regulate MCP-1 secretion in cell models (Shieh et al., 2014; Stokes 
and Surprenant, 2007). There are seven P2X receptors that when activated by ATP, function as 
non-selective cation channels (Costa-Junior et al., 2011). The P2X7 receptor (P2X7R) has a 
uniquely long carboxyl domain that interacts with membrane pores such as pannexin-1, to drive 
inflammation, cell death, and tissue remodeling (Lister et al., 2007; Menzies et al., 2015b). 
P2X7R is highly expressed on macrophages where they regulate the maturation and release of 
cytokines (Ferrari et al., 2006), and on mesangial cells where they promote ECM expansion 
(Solini et al., 2014, 2005). P2X7R is also expressed on non-immune cells, including those of the 
pancreas (Coutinho-Silva et al., 2007) and renal microvasculature (Menzies et al., 2013).  
 
Preclinical research has identified P2X7R as an attractive therapeutic target in kidney diseases 
(Menzies et al., 2016; Solini et al., 2013). However, it is not yet clear whether P2X7R activation 
regulates human diabetic nephropathy or, specifically, if glomerular P2X7R activation underlies 
disease severity. In the present study P2X7R was immunolocalized in renal biopsies from 
diabetic patients and assessed against indicators of renal function and disease. Resident 
glomerular cells facilitate the accrual of macrophages and so P2X7R-mediated proinflammatory 
signaling was investigated in primary human mesangial cells exposed to high glucose. We next 
investigated whether P2X7R-deficiency protected against diabetic renal injury in a murine 
model. In a final experiment, we investigated the therapeutic potential of a P2X7R inhibitor 
(P2X7Ri) following the establishment of hyperglycemia in a rat model of diabetic nephropathy. 
 
Materials and Methods 













Renal biopsy specimens were obtained from patients after informed consent (local ethics 
committee approval 04/Q0406/25), and only materials surplus to clinical need were used. TBM 
biopsies served as controls for diabetic nephropathy. TBM represents the carrier state for 
autosomal recessive Alport Syndrome, in which there are mutations in basement membrane 
collagen typically without renal impairment (Savige et al., 2013). Home Office Science Unit 
licensed all animal procedures under the Animals (Scientific Procedures) Act 1986.  Paraffin 
sections were retrieved from the histology archive at Hammersmith Hospital (approval was 




Primary sections were de-waxed through xylenes and graded alcohols to water. Heat-induced 
epitope retrieval (HIER) was used. Sections were placed in boiling sodium citrate buffer (0.01M; 
pH 6.0) and transferred to a water bath (95oC for 20mins). Sections were then cooled under 
running water for 5 minutes and placed in phosphate-buffered saline (PBS; Sigma-Aldrich, 
Poole, UK). Sections were incubated in 0.3% hydrogen peroxide in PBS (10mins) then washed 
in PBS 3 times for 5 mins each. Sections were incubated in either 10% dry powdered milk 
(Marvel; Premier Foods, St Albans, UK) or 20% normal goat serum (Dako; Carpinteria, CA, 
USA) in PBS for 30 mins at room temperature. 
Primary antibodies for P2X7R (APR-004, Alomone, RRID: AB_2040068; 1:50 murine; 1:100 
human), human CD68 (Clone KP-1, Dako, RRID: B_563621; 1:100), murine CD68 (Clone 
FA-11, Serotec, RRID: AB_323909; 1:200) and collagen IV (Ab6586, Abcam, RRID: 
AB_305584; 1:100) were reconstituted in PBS. Blocking solution was tapped off the slide and 
residual solution blotted. Primary antibody was applied at sufficient volume to cover the section 
(typically 100-200μl). Slides were incubated in a covered, humidified staining chamber for 1hr 
(or overnight for human P2X7R staining). Negative controls comprised omission of primary 
antibody, addition of polyclonal normal rabbit immunoglobulin at an equivalent concentration to 
the primary antibody, and use of primary antibody pre-incubated with the cognate immunizing 
peptide at a 1:1 ratio. Detection was performed by a commercial system (EnVision; Dako, 
Carpinteria, CA, USA). Positive staining appeared as brown deposits. 
Glomerular macrophage (CD68+) number was counted for 20 glomeruli in each section and the 
mean value obtained. The same starting point was used in each section and the first 20 randomly 
encountered glomeruli were included. Interstitial macrophage number was counted for 5 
randomly selected fields of view (x200 magnification) and the mean value obtained. Glomeruli 
were outlined and area measured and type IV collagen calculated as percentage stained area per 
glomerular area. Fifteen glomeruli in each section were scored and the mean value taken. 
 
Primary Human Mesangial Cells 
Primary human mesangial cells (pHMCs; Lonza Biologics, Slough, UK) were cultured in a 
proprietary basal medium supplemented with 5% fetal calf serum (FCS) and gentamicin 
amphotericin-B (Sigma-Aldrich, Poole, UK). Cells were grown at 37C in a humidified 
atmosphere of 5% CO2. Medium was changed every 2-3 days. At 90-100% confluence cells 













MA, USA) or 96-well plates (Nunc, Maxisorp, Thermo Fisher Scientific). Viability of pHMCs 
cultured in the presence of small molecule receptor inhibitors was assessed using a 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt 
(MTS) assay (CellTiter 96; Promega, Madison, WI, USA).  
For experiments cells were grown >70% confluence and then made quiescent by incubation in 
glucose-free RPMI 1640 supplemented with 4mM D-glucose with no serum for 24 hours to 
induce cell cycle synchronization and quiescence prior to treatment. All experiments were done 
in serum free medium. Supplementing glucose-free RPMI 1640 with 30mM D-glucose simulated 
hyperglycemic conditions. L-glucose, the metabolically inactive stereoisomer of D-glucose, was 
added to 4mM D-glucose media at a concentration of 26mM to act as an osmotic control for 
hyperglycemic media. Cells were grown in these conditions for 48 hours without a medium 
change, before collection of supernatants for MCP-1 quantification (below) or cell monolayer 
lysates for protein extraction.  
The effects of a selective P2X7R inhibitor (A438079;  
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=41
18 ; Tocris Bioscience, Bristol, UK), a P2X7R agonist BzATP, (Tocris), on MCP-1 production 
were tested both in the presence and absence of hyperglycemia by supplementing 4mM D-
glucose and 30mM D-glucose media respectively with the appropriate reagent concentration. 
Cells were treated for 30 minutes before collecting supernatants. 
 
Protein Extraction 
Cells were washed twice with ice-cold PBS before adding 100μl of a proprietary cell lysis buffer 
(Invitrogen; Constituents: 10mM Tris pH 7.4, 100mM NaCl, 1mM EDTA, 1mM EGTA, 1mM 
NaF, 20mM Na4P2O7, 2mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% 
deoxycholate) supplemented with 1mM phenylmethanesulfonylfluoride (PMSF; a serine 
protease inhibitor) and protease inhibitor cocktail (P2714, Sigma Aldrich, Poole, UK). 
Monolayers were agitated for 2-3 minutes before scraping and collecting the lysate into 
microcentrifuge tubes. Tubes were rested on ice for 30 minutes, vortexing at 10 minute intervals, 
to ensure complete lysis of cell membranes and solubilization of proteins. The extract was then 
centrifuged at 18,000 x g for 10 minutes at 4C to pellet insoluble cellular debris. Supernatant was 
transferred to a fresh microcentrifuge tube and protein concentration quantified (Pierce BCA kit, 
Thermo Fisher Scientific). 
 
Immunofluorescent staining of P2X7R in pHMC 
Medium was removed and cells washed twice with phosphate Buffered Saline (PBS; Sigma-
Aldrich, Poole, UK). Cells were fixed in 4% paraformaldehyde (PFA; Sigma-Aldrich, Poole, 
UK) in PBS for 5 mins at room temperature and washed 3 times with PBS. Cells were 
permeabilized with 1ml 0.1% Triton x100 in PBS for 10 minutes and washed twice with PBS.  
Non-specific binding sites were blocked by incubation with 5% BSA in 0.1% Triton in PBS for 1 
hour at room temperature. Primary P2X7R antibody (Ab109246; Abcam, RRID: AB_10858498, 
Cambridge, UK) or control (polyclonal IgG or diluent alone) diluted 1:2000 in 10% Marvel in 
PBS (Marvel; Premier Foods, St Albans, UK) was applied overnight.  Cells were then washed 3 













antibody (Alexa 488; Invitrogen, Paisley, UK) diluted in 5% BSA in 0.1% Triton in PBS for 1 
hour in the dark. Cells were washed with PBS, nuclei visualized with DAPI (Vector 
Laboratories, Peterborough, UK). 
 
Quantification of pHMC MCP-1 
A 96-well plate (Nunc ‘Maxisorp’, Thermo Fisher Scientific) was coated with 100μl of an 
affinity- purified mouse anti-human MCP-1 antibody (R&D Systems, Abingdon, UK) at a 
concentration of 2μg/ml diluted in PBS. The plate was covered with an adhesive strip (Appleton 
Woods, Birmingham, UK) and placed at 4C overnight to allow adsorption of antibody to the 
walls of the microplate. Recombinant human MCP-1 (R&D Systems) was used to create a 
reference concentration series to form a 9-point standard series (9.76 - 2500 pg/ml). A ‘blank’ 
sample comprising diluent alone was also included. Following washing with buffer, an affinity-
purified biotinylated polyclonal goat anti-human MCP-1 antibody (100ng/ml; R&D systems, 
Minneapolis, MN, USA) was added and signal amplification performed with streptavidin-HRP 
conjugate. MCP-1 intensity was measured by absorbance (450nm) in the presence of 3,3’,5,5’-
tetramethylbenzidine (TMB; Cambridge Bioscience, Cambridge, UK) in an ELx800 
spectrophotometric microplate reader (Biotek, Winooski, USA) 
 
Animals 
Mice and rats were maintained in a pathogen-free animal facility at Imperial College London 
(Hammersmith Hospital campus) in individually ventilated cages with free access to water and 
standard laboratory diet. Maximum cage occupancy was five mice per cage. All experimental 
animals were male. Gene targeted or littermate control mice were on the CS7BL/6 background. 
P2X7R-deficient mice (Ke et al., 2003) were bred in-house from heterozygote breeding pairs 
provided by GlaxoSmithKline (GSK); with littermate, wild-type (WT) animals used as 
experimental controls. Notably this is a “knock-down” model in which the protein coding murine 
P2X7k alternative transcript is expressed (Nicke et al., 2009). Indeed, Background P2X7R 
mRNA signal was detected in P2X7R-deficient mice, attributed to primer binding of these 
alternative transcripts. Genotype PCR was performed using oligonucleotide primers designed to 
discriminate between native (5’-3’: TGCCCATCTTCTGAACACC;  5’-3’: 
CTTCCTCTTACTGTTTCCTCCC) and disrupted (5’-3’: TGCCCATCTTCTGAACACC; 5’-3’: 
GCAAGGCGATTAAGTTGGG) forms of the P2rx7 gene. Background mRNA signal was also 
detected in P2X7R-deficinet mice, which was attributed to primer binding of alternative 
transcripts. 
 
Type 1 diabetic murine model  
WT and P2X7R-deficient mice aged 8 months or older were randomly divided into two groups: 
receiving either streptozotocin (STZ; Sigma-Aldrich, Poole, UK) 50mg/kg IP dissolved in 
100mM sodium citrate buffer at pH 4.5 (n=8), or citrate buffer alone (n=8). STZ injections were 
performed on 5 consecutive days, initially after a 4-6 hour fast (DiaComp repetitive low-dose 
protocol (mouse)). Blood glucose (BG) was measured 3 weeks after the last injection. Mice were 
immobilized in a restrainer, a tail vein ‘prick’ performed with a 23G needle and a OneTouch 
glucometer (Lifescan, Milpitas, CA, USA) used for glucose measurement. BG >16mmol/l was 













animals with readings falling outside of the desired range were excluded. Urine was collected at 
baseline and week 12; terminal collection of blood and kidney tissues was performed at week 12. 
 
Serum and Biochemical Analysis 
The concentration of mouse urinary albumin in mice was measured using a specific, indirect 
sandwich ELISA (Bethyl Laboratories, Montgomery, TX, USA). Urinary albumin concentration 
values (transformed from ODs using the standard curve and expressed in mg/l) were divided by 
paired urinary creatinine to give the urine albumin to creatinine ratio (uACR; mg/mmol 
creatinine).  Urinary creatinine was measured using the Jaffe reaction. Alkaline picrate was 
produced by adding 2.5ml of 1N sodium hydroxide to 12.5mls of picric acid against standards 
(0.03125 – 2mmol/l) in duplicate and measured at 490nm (ELx800; BioTek, Potton, UK). Serum 
creatinine was measured from whole blood supernatant (centrifugation at 240xg for 5 mins). 
Creatinine was measured by the modified Jaffe reaction in an Olympus AU600 analyzer 
(Olympus, Watford, UK) by the clinical biochemistry laboratory at the Hammersmith Hospital 
(London, UK) 
 
Quantification of Tissue Histology 
Glomerular size was measured on periodic acid-Schiff (PAS)-stained sections. Working 
systematically from one corner of the tissue section, the first 30 glomeruli encountered were 
digitized using a scientific grade digital color camera (Olympus, Tokyo, Japan) at 400x 
magnification. Scale was calibrated using an etched graticule of known diameter. Subsequent 
image analysis was performed using ImagePro software (Media Cybernetics, Bethesda, MD, 
USA). Glomeruli were carefully outlined and each glomerular tuft isolated for surface area 
calculation. At least 30 glomerular areas were calculated from each animal.  
Tissue injury was assessed on Picrosirius red-stained sections to detect collagen under polarized 
light. For each section, 5 randomly selected cortical fields were photographed and digitized at 
200x magnification. Blood vessels larger than neighboring tubules were systematically excluded 
from selected fields to prevent skewing of results due to the collagenous component of vessel 
walls. Using ImagePro, images were converted to gray-scale, rendering birefringent collagen 
fibrils light grey or white. Picrosirius red-stained areas were highlighted automatically. The 
highlighted area could then be measured and expressed as a fraction of the area of the section. 
The mean value for 5 cortical fields of view was calculated for each animal. 
 
Rat Uninephrectomy 
Right uninephrectomy (UNx; n=25) or sham surgery (Sham; n=8) was performed on male Wistar 
Han IGS rats (Crl:WI (Han); Charles River; Margate, UK) weighing 200-250g. Rats were 
anaesthetised with a 1.5-2% isoflurane oxygen mix containing 0.5 l/min air. The right flank was 
shaved and a small incision made to expose the kidney. The adipose capsule of the kidney was 
removed to provide access for a cross-clamp placed over the vascular pedicle and ureter. A silk 
tie was used to ligate the vessels and ureter proximal to the clamp and the kidney removed. The 
clamp was removed and the muscle layer sutured closed using an absorbable stitch in a 













nephrectomy following the procedure described above but with both kidneys left in situ. Rats 
received a single subcutaneous dose of buprenorphine analgesia (0.02mg/kg) at the end of the 
operation. Enrofloxacin (Baytril; Bayer, Leverkusen, Germany) was added to drinking water for 
48 hours post-operatively as antibiotic prophylaxis against wound infection.  
Induction and maintenance streptozotocin-induced diabetes in rats 
Two weeks after surgery, rats were randomly selected to receive a single intravenous (IV) 
injection of STZ (40mg/kg) or citrate buffer vehicle. STZ was dissolved in 100mmol/l citrate 
buffer (pH 4.5) at the point of use. Animals were placed under light anaesthesia with isoflurane 
1.5-2% and STZ or citrate vehicle injected IV via the dorsal penile vein. Water in drinking 
bottles was replaced with 10% sucrose for 48 hours after injection to combat the risk of early 
hypoglycaemia due to insulin release from injured beta cells.  
Venous blood glucose (BG) was checked at 1 week post-injection using a OneTouch glucometer 
(Lifescan, Milpitas, CA, USA). Light anaesthesia was induced with isofluorane and a tail vein 
prick performed with a 23G needle. Animals with a blood glucose of >33.3 mmol/l were 
administered slow-release subcutaneous insulin pellets (Linshin, Toronto, Canada to prevent 
ketoacidosis. 1/8 insulin pellet provides approximately 0.25units insulin per day. BG was 
retested 1 week after insertion and a further 1/8 pellet inserted if BG was persistently >33.3 
mmol/l. This cycle was continued until BG had been titrated equivalently amongst experimental 
rats. 
Administration of a highly selective P2X7R inhibitor to diabetic rats  
Following the establishment of diabetes at week 8, rats were randomly allocated to receive either 
drug vehicle (UNx STZ  Veh; n=8), or P2X7R inhibitor (P2X7Ri) at either 10mg/kg (n=8) or 
50mg/kg (n=9). The doses of the P2X7Ri (AZ11657312; 
www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7722) were based on 
previous in vivo findings (Broom et al., 2008). AZ11657312 was dissolved in a vehicle of 5% 
DMSO 95% 2-hydroxypropyl- beta-cyclodextrin (HPBCD) solution. HPBCD was reconstituted 
as a 20% solution in distilled water. Injection volumes for vehicle-treated animals were 
calculated to ensure weight-based equivalence to both treatment groups. P2X7Ri or vehicle 
injections were administered IP twice daily for 4 weeks. Urine collections were made at baseline 
and 12 weeks in metabolic cages. Following the final urine collection, rats were placed under 
terminal isoflurane anaesthetic and tissues collected post exsanguination.   
Statistics 
All values described in the text and figures are expressed as mean ± standard error unless 
otherwise stated. Statistical comparisons were carried out in GraphPad Prism (GraphPad 
Software, San Diego, CA, USA). Numerical data comparing two groups were analyzed by the 
Student’s t-test for parametric data and Mann-Whitney U test for non-parametric data. 
Categorical data comparing two groups were analyzed with Fisher's exact test. Data comparing 
more than two groups were analyzed by one-way ANOVA with post-tests corrected by the 
Bonferroni method for multiple comparisons for parametric data, and Kruskal-Wallis with 















Renal P2X7R expression is associated with CKD and fibrosis in diabetes 
In renal biopsy sections from diabetic patients, P2X7R immunolocalized to glomeruli (16/30; 
53% patients), either as granular circumferential endothelial deposits in capillary loops or more 
focally within the glomerular mesangium (Fig. 1). The intensity of glomerular P2X7R staining 
varied between glomeruli and interstitial compartments (Suppl. Fig 1a-c). The renal tubules 
stained positively for P2X7R across the majority (27/30; 90%) of patients. In contrast, no 
glomerular or interstitial P2X7R staining was observed in biopsies from patients with thin 
basement membrane (TBM) disease, which served as non-diabetic controls (Suppl. Fig 2a). 
Marked P2X7R expression was seen in a subset of tubular epithelial cells with characteristics of 
the distal tubule (thin cuboidal epithelium with little brush border and open lumens), while 
minimal proximal tubular staining was seen (Suppl. Fig 2b). However, non-diabetic P2X7R-
positive glomerular staining does occur in other human renal diseases, as indicated in the 
example of Class IV proliferative lupus nephritis (Suppl. Fig 2c). 
 
 
Immunohistochemistry for the macrophage marker CD68 was performed on two patient biopsies, 
one with significant glomerular P2X7R immunoreactivity and the other with predominantly 
tubule-interstitial P2X7R expression (Fig. 1b). P2X7R staining appeared more widespread than 
CD68, including endothelial glomerular structures. Most patients (23/30; 77%) also had evidence 
of P2X7R-positive staining within the interstitial compartment (Fig. 1c) and in areas of 
established tubular atrophy where a significant number of infiltrating inflammatory cells were 
apparent (Fig. 1d). Glomerular and interstitial P2X7R staining was not mutually exclusive, co-
existing in 11/30 or 37% of patients. 
 
Renal function was assessed in TBM and a sub-set of the 23 diabetic patients with distinct 
P2X7R interstitial or glomerular localization. Diabetic patients with only renal interstitial P2X7R 
staining (DNInt) had significantly lower estimated glomerular filtration rate (eGFR) compared 
with either patients with only glomerular P2X7R staining (DNGlom) or with TBM control 
patients (Fig. 1e). Interstitial P2X7R staining was also associated with more severe mesangial 
expansion in patients with interstitial P2X7R staining with approximately half of the tissue in 
this compartment undergoing interstitial fibrosis (Fig. 1f); significant expansion of the 
glomerular mesangium was also detected in this group (Fig 1g).  
 
Glomerular mesangial P2X7R activation enhances monocyte chemoattraction 
Glomerular mesangial cells attract circulating monocytes through the release of chemoattractants 
such as MCP-1. Primary human mesangial cells (pHMC’s) were used to determine the role of 
P2X7R-mediated MCP-1 release under high glucose conditions. In controls (4mmol/l D-
glucose), basal MCP-1 levels were not affected by addition of the P2X7R agonist BzATP (Fig. 
2a). Exposure of these cells to high glucose (30mmol/l D-glucose) induced a significant increase 
in MCP-1 release (P<0.05) and this effect was greatly amplified by P2X7R activation 
(P<0.0001). Notably, 30mmol/l D-glucose did not change total P2X7R expression in pHMC 
cells (Fig. 2b).  
 
The P2X7R inhibitor A438079 completely prevented BzATP and high glucose induced secretion 
of MCP-1 (Fig 2c), with no dose-dependence observed over the range 5-50μM, (Suppl. Fig. 3). 













independent experiments with normalization to baseline glucose levels demonstrated a 
reproducible reduction in MCP-1 by A438079 (P<0.05) (Fig. 2d).  
 
P2X7R-deficiency ameliorates glomerular damage in a type I diabetic mouse model 
Type I diabetes mellitus (T1DM) was induced in WT and P2X7R-deficient mice by injection of 
STZ. Three weeks after the final injection, both genotypes had developed similar levels of 
hyperglycemia, which also maintained at 12 weeks (Fig. 2a). Plasma creatinine levels increased 
in both groups following STZ treatment (Suppl. Fig. 5a). Urinary albumin-creatinine levels were 
unchanged by induction of T1DM (Suppl. Fig. 5b). 
 
T1DM increased whole kidney P2X7 mRNA expression in WT mice (Fig. 3b) and glomerular 
P2X7R protein expression was also significantly increased (Fig 3bi). This was not observed in 
P2X7R-deficient mice (Fig 3bii). CD68+ macrophages were increased in the glomeruli of 
diabetic wild-type mice and macrophage accumulation was associated with increased deposition 
of collagen. In contrast, P2X7R-deficient mice were protected from the diabetes-induced rise in 
glomerular macrophage number (Fig. 3c) and there was no increase in collagen IV expression. 
This protection was evident in CD68 stained glomeruli from WT (Fig 3ci) and P2X7R-deficient 
mice (Fig 3cii). Glomerular macrophage accumulation was accompanied by increased collagen 
IV deposition in WT mice (Fig 3d, di), which was not observed in P2X7R-deficient mice (Fig 
3d, dii).  
 
P2X7R inhibition ameliorates macrophage accrual in a model of diabetic nephropathy   
Physical and biochemical data at baseline and week 12 are summarized in Table 1. Body weights 
were similar in all groups at the beginning of the experiment, while diabetic rats gained 
approximately 25% of the weight gained by control groups over the same period. Kidney weight 
to body weight ratio more than doubled in UNx STZ Veh rats compared with UNx Veh controls 
(p<0.001) and increased by ~30% compared with sham-operated and UNx controls (p<0.001). 
Rats treated with P2X7Ri had no change in kidney weight: body weight ratio. 
 
Table 1:  Summary of weight gain and baseline blood glucose in rats. Data from 
control (Sham and UNx Veh), diabetic (UNx STZ Veh) and P2X7Ri groups at doses stated. 




















217.2 ± 13.3 215.3 ± 7.4 224.4 ± 10.3  
% Weight 
gain (Wk 0 
to Wk12) 
84.0 ± 15.8  84.9 ± 18.7  18.5 ± 8.6a,b  23.3 ± 6.1 













Wk 0  
BG 
(mmol/l) 






2.70 ± 0.29  3.95 ± 0.23 
c
  
8.17 ± 0.85 a,b 7.88 ± 0.89 
a,b 7.24 ± 0.98a,b 
 
 
BG was similar across all groups at the beginning of the experiment (Table 1). Hyperglycemia 
was stably maintained in diabetic animals by insertion of insulin pellets such that hyperglycemia 
was tightly controlled within the UNx STZ groups (Fig. 4a). Hyperglycemic levels were 
unaffected by P2X7Ri at either dose. This finding is consistent with observations in P2X7R-
deficient mice where STZ-injection caused hyperglycemia. Both terminal plasma creatinine and 
albumin excretion rate (AER) were significantly increased in the diabetic groups (Fig. 4b, c). 
P2X7Ri did not reduce creatinine levels or albuminuria.  
 
P2X7R was immunolocalized in renal sections. In control kidneys removed at UNx, marked 
basolateral staining was observed in a subpopulation of tubules and vascular endothethial cells 
(Fig. 5a), but no significant glomerular positivity was detected. The remaining kidney was 
assessed 12 weeks later (UNx Veh) and a similar staining pattern was observed (Fig. 5b). In the 
UNx STZ Veh group, P2X7R was highly expressed in glomeruli where marked capillary loop 
staining became visible (Fig. 5c) additional constitutive expression of P2X7R was also detected 
in the distal convoluted tubule. Antibody epitope specificity was demonstrated in a UNx STZ 
Veh section (Fig. 5d). 
 
Renal macrophage infiltration was assessed by CD68 immunolocalization and quantified 
separately in glomerular and tubulointerstitial compartments (Fig. 6). Interstitial macrophage 
number was increased ~50% in diabetic UNx rats compared with both sham-operated and UNx 
controls (p<0.05; Fig. 6a). Importantly, treatment with the P2X7Ri reduced interstitial 
macrophage inhibition in diabetic UNx rats, returning macrophage numbers to baseline levels. 
Representative sections comparing sham kidneys (Fig. 6b), in which there were minimal 
numbers of macrophages, and UNx STZ Veh kidneys (Fig. 6c) showed interstitial macrophage 
accumulation in the UNx diabetic kidneys. P2X7Ri at 10m/kg (Fig. 6d) was not sufficient to 
reduce macrophage accumulation, however, 50mg/kg was sufficient (Fig. 6e). In contrast to the 
interstitial compartment, glomerular macrophage number was not increased in diabetic rats 















It is increasingly evident that P2X7R contributes to chronic inflammatory disorders: P2X7R 
activation promotes formation of the cryopyrin (NLRP3) inflammasome and the release of 
cytokines (Ferrari et al., 2006; Lister et al., 2007; Solle et al., 2001). P2X7R expression is 
increased in models of hypertension and diabetes (Ji et al., 2012a, 2012b; Menzies et al., 2015b; 
Vonend et al., 2004), both major risk factors for CKD in humans. Deletion or blockade of 
P2X7R protects against antibody-induced glomerular injury (Taylor et al., 2009; Turner et al., 
2007) and deoxycorticosterone acetate salt-induced fibrosis (Ji et al., 2012b). Constitutively high 
renal P2X7R expression, impairs the pressure-natriuresis response and enhances susceptibility to 
renal vascular injury in rats (Menzies et al., 2013). Acute P2X7R antagonism improves renal 
blood flow, medullary perfusion and oxygenation in angiotensin-II-induced hypertension 
(Menzies et al., 2015a).  
 
In the present study we found high P2X7R expression in renal biopsy samples from patients with 
diabetic nephropathy. This is consistent with detection of P2X7R in nephrectomy tissue from 
patients with type 2 diabetes and renal cell carcinoma (Solini et al., 2013). Glomerular 
expression of P2X7R was prevalent at ~50% in diabetes but was not observed in TBM disease 
controls. P2X7R-deficient mice were protected from the STZ-induced glomerular damage 
observed in WT controls. This suggests that many short-term preclinical models of increased 
glomerular P2X7R expression likely reflect early pro-inflammatory injury found in human 
glomerulosclerosis. As such, P2X7R activation in the renal vasculature or mesangium under 
hyperglycemic (Kreft et al., 2016), or hypertensive (Conway et al., 2012; Menzies et al., 2015a) 
conditions may also directly impair renal function in diabetic nephropathy. Moreover, 
progression of diabetic nephropathy requires coordination of glomerular and interstitial 
compartments (Bohle et al., 1991), typically from a combination of hyperglycemia and 
hypertension (Conway et al., 2012). Indeed, more severe CKD and interstitial fibrosis were 
observed in biopsies in which there was high interstitial P2X7R expression and interstitial 
fibrosis is typically found in more advanced disease (Liu, 2011). 
 
Our observations in patients and in vitro studies in pHMCs suggest that activation of mesangial 
P2X7R may enhance early glomerular macrophage recruitment leading to injury. MCP-1 attracts 
macrophages that promote pro-inflammatory processes (Conti and DiGioacchino, 2001; Rovin et 
al., 1994). We have previously demonstrated that macrophage accumulation is reduced in 
P2X7R-deficient mice, as are urinary MCP-1 levels (Taylor et al., 2009). Although macrophages 
can transition between pro- and anti- inflammatory phenotypes, depending on the local 
microenvironment (Martinez and Gordon, 2014), P2X7R preferentially activates M1 polarized 
pro-inflammatory macrophages (de Torre-Minguela et al., 2016); therefore, P2X7R activation 
promotes the accumulation of deleterious pro-inflammatory macrophages.  
 
Preclinical models of P2X7R-deficiency do not fully recapitulate the clinical reality found in 
patients. However, the P2X7R-deficient mouse model did allow us to demonstrate that lack of 
canonical P2X7R does not prevent STZ-induced hyperglycemia. Instead, P2X7R-deficiency 
appears to protect the kidney since these mice had reduced macrophage accrual and collagen IV 
deposition indicating protection against expansion of extracellular matrix, a hallmark of fibrosis, 














The P2X7Ri had significant effectiveness in reducing renal macrophage accrual following the 
establishment of diabetes. Reduction of renal interstitial macrophages with a P2X7Ri may be 
therapeutically beneficial in the longer-term in human diabetic nephropathy, since we identified 
that these patients have more severe CKD and fibrosis. An important limitation of this model 
was the lack of more severe glomerular and tubulointerstitial damage seen in human diabetic 
nephropathy. Indeed, glomerular macrophage accrual was never increased in the rat model. This 
may be unsurprising however since many preclinical kidney disease models fail to capture the 
severity of human disease (Mullins et al., 2016). The lack of impact of P2X7R blockade on 
albumin excretion is consistent with the experimental findings in the P2X7R-deficient mice and 
suggests that P2X7R does have an important mechanistic role in the early development of 
glomerular damage and albuminuria; although this is despite apparent upregulation of P2X7R in 
the glomeruli at 12 weeks in both mice and rats with STZ-induced diabetes. Collectively, this 
study demonstrates the potential for selective P2X7Ri to reduce renal macrophage accumulation, 
supporting future investigations of P2X7R inhibition in diabetes and other renal diseases 
characterized by macrophage infiltration.  
 
Prophylactic use of a P2X7Ri has proven reno-protective in multiple kidney disease models 
(Menzies et al., 2016), but it is unclear whether blockade can reverse an established fibrotic 
phenotype. The data presented here suggest that P2X7Ri may have specific anti-inflammatory 
and anti-macrophage role in diabetic nephropathy. Further longitudinal studies are required to 
determine whether P2X7Ri can offer real clinical benefit to early, and more established fibrotic 
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Figure 1. Renal P2X7R in human diabetic nephropathy. Patient biopsies expressing (a) 
P2X7R protein and (b) CD68+ monocytes in glomeruli indicated with black arrows. In the most 
severe cases (c) P2X7R staining and (d) CD68+ staining of the interstitium overlapped in regions 
of inflammation. Estimated glomerular filtration rate (eGFR) (e), fibrosis (f) and mesangial 
expansion (g) in patients with interstitial (DNInt=7), glomerular (DNGlom=5) P2X7R 
immunoreactivity compared to thin basement membrane (TBM=3) controls subjects. *P<0.05, 
**P<0.01 DNint vs. TBM. a, b x200mag c, d x100mag  
 
Figure 2. Glomerular mesangial P2X7R and MCP-1. Activation of P2X7R with BzATP 
increased MCP-1 secretion from pHMCs under high glucose conditions (a). P2X7R protein 
expression in mesangial cells under normal and high glucose conditions (b). Effect of a P2X7R 
inhibitor (A438079) on MCP-1 secretion (c). Subtraction of normal glucose MCP-1 release 
highlighted the absolute magnitude of MCP-1 reduction by P2X7R blockade alone across 9 
separate experiments (d). *P<0.05, **P<0.01, ***P<0.001 vs baseline; †P<0.05, ††P<0.01, 
†††P<0.01 versus 30mM D pHMC; ‡‡‡‡P<0.0001 4mM D + BzATP vs. 30mM D + BzATP.  
 
Figure 3. P2X7R-deficient mice and STZ-induced glomerular macrophage accrual. Rise in 
blood glucose following STZ injections (a). Renal P2X7 mRNA increased with STZ treatment in 
control mice but not P2X7R-deficient mice (b). Glomerular P2X7R staining in WT (bi) and 
P2X7R-deficient mice (bii). Tubular P2X7R-positive immunoreactivity was observed in all 
sections, presumed to represent expression of an alternative splice variant (P2X7Rk) in otherwise 
P2X7R-deficient mice. Distinct interstitial (non-tubular) staining was not observed. Glomerular 
macrophage accumulation increased in WT mice following STZ (c). Glomerular CD68 staining 
in WT (ci) and P2X7R-deficient mice (cii). Glomerular type IV collagen deposition increased in 
WT following STZ (d). Glomerular collagen IV staining in WT (di) and P2X7R-deficient mice 
(dii). *P<0.05, **P<0.01, ***P<0.001. WT: wild-type. STZ: streptozotocin. KO: P2X7R-
deficient mice. b-d x200 mag.  
 
Figure 4. Effect of P2X7R inhibitor on blood glucose levels and kidney function. Blood 
glucose measured at week 12 (a). Serum creatinine concentration in terminal serum (b) and 
albumin excretion rate (AER) (c). *P<0.05 UNx STZ groups vs. Sham or UNx Veh. 
****P<0.0001 UNx STZ groups vs. Sham or UNx Veh. Measurements were made at 12 weeks. 
 
Figure 5. Immunolocalization of P2X7R in rat kidney. Normal Wistar Han kidney collected 
during UNx (a). Kidney tissue from a week 12 vehicle-injected UNx Wistar Han rat (b). 
Representative P2X7R staining in a UNx STZ Veh rat kidney at week 12 (c). P2X7R staining in 
and STZ-injected UNx rat where anti-P2X7 antibody was pre-absorbed with its conjugate 
peptide (1:1) to demonstrate antibody specificity (d). a-d x200 mag. 
 
Figure 6. Effect of P2X7R inhibitor on diabetic renal macrophage accrual. Interstitial 













treated rat kidney with minimal macrophage staining (b), UNx STZ Drug vehicle-treated diabetic 
rat kidney with interstitial macrophage accumulation (c), Unx STZ rat treated with 10mg/kg 
P2X7Ri (d), and 50mg/kg P2X7Ri- treated rat kidney (e). Glomerular macrophage abundance 
(f). Measurements were made at 12 weeks. *P<0.05 UNx STZ groups vs. Sham or UNx Veh NS; 





Suppl. Fig 1. Immunohistochemistry of P2X7R in diabetic nephropathy.  Typical appearance 
of tubules in diabetic nephropathy (a). Glomerular P2X7R expression in diabetic nephropathy 
(b). P2X7R-positive interstitial cells in diabetic nephropathy (c). Biopsy tissue probed with 
P2X7R antibody after prior incubation with specific immunizing peptide in 1:1 ratio (d). a-d 
x200 mag. 
 
Suppl. Fig 2. Immunohistochemistry for P2X7R in Thin Basement Membrane disease and 
Lupus Nephritis Typical appearance of a glomerulus from a patient with TBM lesion, with no 
appreciable P2X7R staining (a). Tubular appearance in TBM disease (b). Glomerulus from a 
patient with class IV proliferative lupus nephritis (c). a-c x200 mag. 
Suppl. Fig 3. P2X7 inhibitor (A438079) reduced MCP-1 release from high concentration 
glucose and BzATP stimulated mesangial cells. No apparent dose-dependence was seen over a 
range of concentrations of A438079 from 5 - 50 μM, with all proving equally effective (all 
comparisons to 30mM D-glucose (D) group). ** P<0.01, ***P<0.001 
 
Suppl. Fig. 4. Assessment of A438079 cytotoxicity using MTS assay. A438079 had no effect 
on cell viability over the 5 -50μM concentration range. Normoglycemic RPMI 1640 medium was 
supplemented with the appropriate concentrations of inhibitor or drug vehicle and cultures 
incubated at 37oC for 48 hours.  D: D-glucose. NS: Not significant. 
 
Suppl. Fig. 5. Urinary Creatinine levels in diabetic mice (a) Serum creatinine at week 12. 
Creatinine was elevated in both diabetic groups compared to controls, but was equivalent in WT 
and P2X7R-deficient diabetic mice. (b) uACR at week 12. uACR was elevated in both diabetic 
groups compared to controls, but failed to reach statistical signficance. A trend towards higher 
uACR values was seen in STZ-treated P2X7R-deficient mice compared to WT, but with a wide 
standard deviation of values in the former group. *** P<0.001, NS: Not significant. 
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